Drug
Azilsartan clinical trials
Also written TAK-536.
- studies test it
- 22
- open now
- 1
- in phase 3
- 7
- first study started
- 2004
Keep track of what changes. Save the azilsartan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
22 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
- Phase 3
- 7
- Phase 4
- 3
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 5
Takeda (12) · Lee's Pharmaceutical Limited (3) · Celltrion (1) · Sogo Rinsho Médéfi Co., Ltd. (1) · Nara Medical University (1) · National Medical Research Center for Therapy and Preventive Medicine (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Pioglitazone (2) · Rosuvastatin (1) · Valsartan (1) · Losartan (1) · Hydrochlorothiazide (1) · Amlodipine (1)
Studies
Open first, then newest update. How each study uses azilsartan is read from its arms, and is right about nine times in ten.
Testing it · 22
- Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary InterventionRecruitingNot applicableNational Medical Research Center for Therapy and Preventive MedicineNCT07683585Written as Amlodipine + Azilsartan
- A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood PressureCompletedPhase 3TakedaNCT04668157Written as TAK-536
- Azilsartan in Patients With Diabetic Kidney Disease and HypertensionStatus unknownNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05753696Written as Azilsartan
- A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult VolunteersCompletedPhase 1CelltrionNCT05002244Written as CTL0801 (Azilsartan)
- A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With HypertensionCompletedPhase 3TakedaNCT02791438Written as Azilsartan
- A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric FormulationCompletedPhase 1TakedaNCT03434977Written as TAK-536
- A Phase 1, Bio-equivalence Study of TAK-536 Pediatric FormulationCompletedPhase 1TakedaNCT03042299Written as TAK-536
- Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy VolunteersCompletedPhase 1Lee's Pharmaceutical LimitedNCT02786082Written as 20mg Azilsartan Tablets
- Azilsartan in Chinese Patients With Mild and Moderate HypertensionCompletedPhase 3Lee's Pharmaceutical LimitedNCT02609490Written as Azilsartan tablets
- Bioequivalence Study of Azilsartan Tablets in Chinese Healthy VolunteersCompletedPhase 1Lee's Pharmaceutical LimitedNCT03652792Written as Azilsartan (Zhaoke)
- A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-RCompletedPhase 4TakedaNCT02079805Written as Azilsartan
- A Bioequivalence Study of TAK-536 Pediatric FormulationCompletedPhase 1TakedaNCT02401464Written as TAK-536 Tablet
- A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.WithdrawnPhase 4TakedaNCT02400775Written as Azilsartan
- A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With HypertensionCompletedPhase 3TakedaNCT02451150Written as Azilsartan
- Azilsartan Circadian and Sleep PressureCompletedNot applicableSogo Rinsho Médéfi Co., Ltd.NCT01762501Written as Azilsartan
- Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential HypertensionStatus unknownPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT02407210Written as azilsartan
- Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive PatientsStatus unknownPhase 2/3Hospital General de México Dr. Eduardo LiceagaNCT02235519Written as Azilsartan 40 mg.
- New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure LoweringCompletedPhase 4Nara Medical UniversityNCT01609959Written as Azilsartan
- Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes MellitusCompletedPhase 2TakedaNCT00762736Written as Pioglitazone and azilsartan
- Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential HypertensionCompletedPhase 2TakedaNCT01289132Written as Azilsartan
See all 22 studies that test azilsartan →
Given in every arm · 1 — azilsartan is usual care beside what is tested
Codes
What other systems call azilsartan · ClinicalTrials.gg INT005122
- MeSH (NLM) C521273azilsartanOne source NLM
- UNII (FDA) F9NUX55P23AZILSARTANConfirmed FDA, NLM, Wikidata
- RxNorm 1091643Confirmed FDA, Wikidata
- Wikidata Q27074832azilsartanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C75107AzilsartanOne source FDA
- DrugBank DB21772One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C521273 | azilsartan | One source NLM |
| UNII (FDA) | F9NUX55P23 | AZILSARTAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1091643 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27074832 | azilsartan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C75107 | Azilsartan | One source FDA |
| DrugBank | DB21772 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.